Nine Point Two Capital LLC Altimmune, Inc. Transaction History

Nine Point Two Capital LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $186,601 - $749,524	44,535 Added 279.27%	60,482 $255,000
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $139,376 - $262,328	15,947 New	15,947 $262,000
Q1 2022 May 16, 2022	SELL	$5.9 - $9.45 $219,291 - $351,237	-37,168 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$8.69 - $12.48 $322,989 - $463,856	37,168 New	37,168 $340,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Nine Point Two Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Nine Point Two Capital LLC with notifications on news.